Darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead-in phase results. Concomitant G-CSF use in maintaining an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results